Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
International Drug Development Institute
IDDI BRINGS THE FULL SPECTRUM OF TRIAL DESIGN, CLINICAL DATA COLLECTION, ANALYSIS AND REPORTING TO YOUR CLINICAL DEVELOPMENT PROGRAMS.
• PRIVATELY-HELD COMPANY FOUNDED BY MARC BUYSE, ScD, IN 1991
• BIOSTATISTICS AND ECLINICAL SOLUTIONS:
• Protocol plan
• Central randomization (IWRS)
• Clinical information administration
• Electronic information catch (EDC)
• Biostatistics
• Medical composing
• Full-benefit with chose accomplices
• IN-HOUSE DEVELOPED WEB SYSTEMS FULLY INTEGRATED WITH EDC SYSTEM
• ID-net™, an electronic incorporated randomization, coordinated into IDDIs chosen EDC
framework
• ID-supply™, a brought together medication supply administration framework.
• ID-code™, a coding framework in view of MedDRA® and WHO-DRUG word references
• THERAPY SPECIFIC EXPERTISE: Center concentration in oncology and ophthalmology with
generous involvement in cardiovascular, irresistible ailments, CNS, Immunology, biosimilars,
vagrant medications and restorative gadgets.
• GLOBAL REACH BUSINESS WITH OFFICES IN EUROPE AND USA: Headquartered in Louvain-la-
Neuve (Belgium) with workplaces in Raleigh (NC), Boston (MA) and San Francisco (CA).
• CLIENT BASE: Incorporates Big Pharmas, driving Biotechs and new companies, Academic Groups
and CROs.
• 80% REPEAT BUSINESS
• STAFF OF 90 representatives (77,6 FTE) including 3MDs, 5PhDs, 1 ScD
• MISSION: IDDIs main goal is to advance the clinical improvement of medications, biologics,
biomarkers and gadgets, utilizing a one of a kind blend of cutting edge biostatistics and
imaginative clinical information administration innovation.
IDDI HAS BEEN INVOLVED IN OVER 900 CLINICAL TRIALS SINCE ITS INCEPTION.
In the course of the most recent five years, IDDI has led 336 stage I-IV clinical trials.
IDDIs expansive scope of ability is reflected in its master productions all through different medicinal and factual diaries (accessible on demand) and through its nearness at real gatherings and congresses (list gave on demand).
Therapeutic areas
Experience over the last 5 years
(# of trials)
Global Experience
(# of trials)
ONCOLOGY
224 cancer trials
586 trials
The company has been involved in 12 market approvals of anti-cancer therapies.
OPHTHALMOLOGY
28 ophthalmic trials
99 trials
IDDI’s contributed methodology and integrated technology supported Macugen® market approval.
CARDIOLOGY
11 cardiology trials
48 trials
CNS (Central Nervous System)
15 CNS trials
31 trials
Musculoskeletal (Connective Tissue)
17 trials
27 trials
BIOSIMILARS
Currently involved in 10 clinical trials, primarily related to the second generation of monoclonal antibodies.
Orphan Drugs
IDDI has worked on 38 orphan drug studies
OTHER SIGNIFICANT AREAS
• Infectious disease, central nervous system, autoimmune diseases, nutrition.
• Biosimilars.
• Medical Devices:
• Our procedures adjust to therapeutic gadget thinks about, both for pilot and critical reviews.
• We help our customers accomplish the CE checking and FDA endorsements for medicinal gadgets.
• IDDI has effectively helped a cardio-vascular gadget endorsed in the US, and the approval of a disease determination likewise submitted to the FDA.
IDDI AT OUTSOURCING IN CLINICAL TRIALS ISRAEL, 2017
IDDI displaying at Outsourcing in Clinical Trials Israel, 2017 Arena Conference in Tel Aviv.
Meet our expert and find how IDDIs clinical trial information aptitude prompts to FDA/EMA approval and how we alleviate dangers amid the whole clinical trial handle! Stop by stall 20!
This remarkable occasion is the main clinical outsourcing stage in the Middle East for the biopharma and medicinal gadget industry.
The gathering expects to give participants the elite chance to talk about how they can build up their outsourcing systems and enhance operational productivity in clinical trials to remain cost and time-powerful. Delegates at this enlightening two day occasion will likewise be able to coordinate with industry associates and specialist co-ops and go to intriguing introductions conveyed by senior figures from the most inventive organizations in the Israeli life sciences industry.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi